Cargando…

Field-friendly serological tests for determination of M. leprae-specific antibodies

Early detection of leprosy is key to reduce the ongoing transmission. Antibodies directed against M. leprae PGL-I represent a useful biomarker for detecting multibacillary (MB) patients. Since efficient leprosy diagnosis requires field-friendly test conditions, we evaluated two rapid lateral flow as...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hooij, Anouk, Tjon Kon Fat, Elisa M., van den Eeden, Susan J. F., Wilson, Louis, Batista da Silva, Moises, Salgado, Claudio G., Spencer, John S., Corstjens, Paul L. A. M., Geluk, Annemieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566372/
https://www.ncbi.nlm.nih.gov/pubmed/28827673
http://dx.doi.org/10.1038/s41598-017-07803-7
_version_ 1783258537153003520
author van Hooij, Anouk
Tjon Kon Fat, Elisa M.
van den Eeden, Susan J. F.
Wilson, Louis
Batista da Silva, Moises
Salgado, Claudio G.
Spencer, John S.
Corstjens, Paul L. A. M.
Geluk, Annemieke
author_facet van Hooij, Anouk
Tjon Kon Fat, Elisa M.
van den Eeden, Susan J. F.
Wilson, Louis
Batista da Silva, Moises
Salgado, Claudio G.
Spencer, John S.
Corstjens, Paul L. A. M.
Geluk, Annemieke
author_sort van Hooij, Anouk
collection PubMed
description Early detection of leprosy is key to reduce the ongoing transmission. Antibodies directed against M. leprae PGL-I represent a useful biomarker for detecting multibacillary (MB) patients. Since efficient leprosy diagnosis requires field-friendly test conditions, we evaluated two rapid lateral flow assays (LFA) for detection of Mycobacterium leprae-specific antibodies: the visual immunogold OnSite Leprosy Ab Rapid test [Gold-LFA] and the quantitative, luminescent up-converting phosphor anti-PGL-I test [UCP-LFA]. Test performance was assessed in independent cohorts originating from three endemic areas. In the Philippine cohort comprising patients with high bacillary indices (BI; average:4,9), 94%(n = 161) of MB patients were identified by UCP-LFA and 78%(n = 133) by Gold-LFA. In the Bangladeshi cohort, including mainly MB patients with low BI (average:1), 41%(n = 14) and 44%(n = 15) were detected by UCP-LFA and Gold-LFA, respectively. In the third cohort of schoolchildren from a leprosy hyperendemic region in Brazil, both tests detected 28%(n = 17) seropositivity. Both rapid tests corresponded well with BI(p < 0.0001), with a fairly higher sensitivity obtained with the UCP-LFA assay. However, due to the spectral character of leprosy, additional, cellular biomarkers are required to detect patients with low BIs. Therefore, the UCP-LFA platform, which allows multiplexing with differential biomarkers, offers more cutting-edge potential for diagnosis across the whole leprosy spectrum.
format Online
Article
Text
id pubmed-5566372
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55663722017-08-23 Field-friendly serological tests for determination of M. leprae-specific antibodies van Hooij, Anouk Tjon Kon Fat, Elisa M. van den Eeden, Susan J. F. Wilson, Louis Batista da Silva, Moises Salgado, Claudio G. Spencer, John S. Corstjens, Paul L. A. M. Geluk, Annemieke Sci Rep Article Early detection of leprosy is key to reduce the ongoing transmission. Antibodies directed against M. leprae PGL-I represent a useful biomarker for detecting multibacillary (MB) patients. Since efficient leprosy diagnosis requires field-friendly test conditions, we evaluated two rapid lateral flow assays (LFA) for detection of Mycobacterium leprae-specific antibodies: the visual immunogold OnSite Leprosy Ab Rapid test [Gold-LFA] and the quantitative, luminescent up-converting phosphor anti-PGL-I test [UCP-LFA]. Test performance was assessed in independent cohorts originating from three endemic areas. In the Philippine cohort comprising patients with high bacillary indices (BI; average:4,9), 94%(n = 161) of MB patients were identified by UCP-LFA and 78%(n = 133) by Gold-LFA. In the Bangladeshi cohort, including mainly MB patients with low BI (average:1), 41%(n = 14) and 44%(n = 15) were detected by UCP-LFA and Gold-LFA, respectively. In the third cohort of schoolchildren from a leprosy hyperendemic region in Brazil, both tests detected 28%(n = 17) seropositivity. Both rapid tests corresponded well with BI(p < 0.0001), with a fairly higher sensitivity obtained with the UCP-LFA assay. However, due to the spectral character of leprosy, additional, cellular biomarkers are required to detect patients with low BIs. Therefore, the UCP-LFA platform, which allows multiplexing with differential biomarkers, offers more cutting-edge potential for diagnosis across the whole leprosy spectrum. Nature Publishing Group UK 2017-08-21 /pmc/articles/PMC5566372/ /pubmed/28827673 http://dx.doi.org/10.1038/s41598-017-07803-7 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
van Hooij, Anouk
Tjon Kon Fat, Elisa M.
van den Eeden, Susan J. F.
Wilson, Louis
Batista da Silva, Moises
Salgado, Claudio G.
Spencer, John S.
Corstjens, Paul L. A. M.
Geluk, Annemieke
Field-friendly serological tests for determination of M. leprae-specific antibodies
title Field-friendly serological tests for determination of M. leprae-specific antibodies
title_full Field-friendly serological tests for determination of M. leprae-specific antibodies
title_fullStr Field-friendly serological tests for determination of M. leprae-specific antibodies
title_full_unstemmed Field-friendly serological tests for determination of M. leprae-specific antibodies
title_short Field-friendly serological tests for determination of M. leprae-specific antibodies
title_sort field-friendly serological tests for determination of m. leprae-specific antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566372/
https://www.ncbi.nlm.nih.gov/pubmed/28827673
http://dx.doi.org/10.1038/s41598-017-07803-7
work_keys_str_mv AT vanhooijanouk fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies
AT tjonkonfatelisam fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies
AT vandeneedensusanjf fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies
AT wilsonlouis fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies
AT batistadasilvamoises fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies
AT salgadoclaudiog fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies
AT spencerjohns fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies
AT corstjenspaullam fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies
AT gelukannemieke fieldfriendlyserologicaltestsfordeterminationofmlepraespecificantibodies